Literature DB >> 12221861

An overview of chronic urticaria.

Vincent S Beltrani1.   

Abstract

Acknowledging urticaria as a symptom of mast cell degranulation is stressed. The biology of the mast cell, and the recognized immunologic and non-immunologic mast cell secretagogues are individually discussed along with mechanisms of activation and mediators released. The major, preformed mediator histamine in the skin produces a prototypic, short-lived urticaria, however, the clinical spectrum and pattern of "hives" indicate that other mediators contribute to the polymorphism and variable behavior of this symptom. The clinical assessment is almost exclusively restricted to the history and physical examination. Features to review and examine are presented. The cause of "acute" urticaria is identifiable (by history) in the majority of patients, and except for hives that accompany an anaphylactic reaction, these patients rarely present to the physician for care. The persistent, or "chronic" hiver whose history cannot elicit a cause, is rarely triggered by an individual trigger, despite extensive professional evaluation. Evidence to support changing the chronological, "acute" and "chronic" classification of urticaria to "identifiable" and "non-identifiable" triggered urticaria is discussed, as is the futility of extensive, costly laboratory work-ups. The natural history of urticaria reveals that management should be directed toward allowing the patient to maintain an acceptable quality of life (with or without some urticaria), until the episode resolves.

Entities:  

Mesh:

Year:  2002        PMID: 12221861     DOI: 10.1385/CRIAI:23:2:147

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  95 in total

1.  Urticaria in patients with hepatitis A virus infection.

Authors:  S Dollberg; Y Berkun; E Gross-Kieselstein
Journal:  Pediatr Infect Dis J       Date:  1991-09       Impact factor: 2.129

2.  Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients.

Authors:  A Leznoff; G L Sussman
Journal:  J Allergy Clin Immunol       Date:  1989-07       Impact factor: 10.793

Review 3.  Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual.

Authors:  S A Bock; H A Sampson; F M Atkins; R S Zeiger; S Lehrer; M Sachs; R K Bush; D D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  1988-12       Impact factor: 10.793

Review 4.  Urticaria and angioedema.

Authors:  K P Mathews
Journal:  J Allergy Clin Immunol       Date:  1983-07       Impact factor: 10.793

5.  Scabies: a cause of generalized urticaria.

Authors:  J A Witkowski; L C Parish
Journal:  Cutis       Date:  1984-03

6.  The association of chronic urticaria and angioedema with autoimmune thyroiditis.

Authors:  I Turktas; N Gokcora; S Demirsoy; N Cakir; E Onal
Journal:  Int J Dermatol       Date:  1997-03       Impact factor: 2.736

7.  Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects.

Authors:  T C Theoharides; L K Singh; W Boucher; X Pang; R Letourneau; E Webster; G Chrousos
Journal:  Endocrinology       Date:  1998-01       Impact factor: 4.736

Review 8.  Dermographism: a review.

Authors:  R C Wong; J A Fairley; C N Ellis
Journal:  J Am Acad Dermatol       Date:  1984-10       Impact factor: 11.527

9.  Use of IgE antibody determinations in cutaneous Coelenterate envenomations.

Authors:  J W Burnett; G J Calton
Journal:  Cutis       Date:  1981

10.  Aspirin-induced urticaria--a clinical study.

Authors:  I Grzelewska-Rzymowska; M Szmidt; J Rozniecki
Journal:  J Investig Allergol Clin Immunol       Date:  1992 Jan-Feb       Impact factor: 4.333

View more
  6 in total

1.  Chronic urticaria.

Authors:  Sandeep Sachdeva; Vibhanshu Gupta; Syed Suhail Amin; Mohd Tahseen
Journal:  Indian J Dermatol       Date:  2011-11       Impact factor: 1.494

2.  Chronic urticaria in most patients is poorly controlled. Results of the development, validation, and real life application of the arabic urticaria control test.

Authors:  Carla Irani; Souheil Hallit; Karsten Weller; Marcus Maurer; Carla El Haber; Pascale Salameh
Journal:  Saudi Med J       Date:  2017-12       Impact factor: 1.484

3.  The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.

Authors:  M Maurer; M Abuzakouk; F Bérard; W Canonica; H Oude Elberink; A Giménez-Arnau; C Grattan; K Hollis; A Knulst; J-P Lacour; C Lynde; A Marsland; D McBride; A Nakonechna; J Ortiz de Frutos; C Proctor; G Sussman; C Sweeney; H Tian; K Weller; D Wolin; M-M Balp
Journal:  Allergy       Date:  2017-07-10       Impact factor: 13.146

Review 4.  Clinical review: The suggested management pathway for urticaria in primary care.

Authors:  Dermot Ryan; Luciana K Tanno; Elizabeth Angier; Evangéline Clark; David Price; Torsten Zuberbier; Marcus Maurer
Journal:  Clin Transl Allergy       Date:  2022-10-05       Impact factor: 5.657

5.  Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.

Authors:  Jonathan Graham; Doreen McBride; Donald Stull; Anna Halliday; Stamatia Theodora Alexopoulos; Maria-Magdalena Balp; Matthew Griffiths; Ion Agirrezabal; Torsten Zuberbier; Alan Brennan
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

Review 6.  Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients.

Authors:  Kiran Godse; Murlidhar Rajagopalan; Mukesh Girdhar; Sanjiv Kandhari; Bela Shah; Prashant N Chhajed; Sushil Tahiliani; D S Krupa Shankar; Vijay Somani; Vijay Zawar
Journal:  Indian Dermatol Online J       Date:  2016 Jan-Feb
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.